Diaryl ureas for diseases mediated by PDGFR
US8796250B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 19, 2004 |
| Grant date | Aug 5, 2014 |
| Priority date | — |
| Expiry date | Mar 17, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61L2300/416
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for treating and/or preventing conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR) by administering diaryl ureas of Formula I. The present invention also provides devices and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect or injure the vascular system, and graft rejection following transplantation of a donor tissue into a host, where a stent or other omplantable device comprises an effective amount of diaryl ureas of Formula I.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.